Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
CytRx highlights Orphazyme data from Arimoclomol trial in NPC treatment » 08:17
08/24/21
08/24
08:17
08/24/21
08:17
CYTR

CytRx

/

+

, ORPH

Orphazyme

$5.33 /

+0.33 (+6.60%)

CytRx (CYTR) highlighted…

CytRx (CYTR) highlighted that Orphazyme A/S (ORPH) published the results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C, NPC, in the peer-reviewed Journal of Inherited Metabolic Disease, JIMD. We are pleased to share the data from our Phase 2/3 trial in JIMD. NPC is a rare, inherited progressive neurodegenerative disorder with a high unmet medical need for disease-modifying treatment options. This trial demonstrated a statistically significant and clinically meaningful treatment effect of arimoclomol in NPC supported by significant and consistent effects across several disease- and pharmacodynamic biomarkers. We believe these data establish the potential of arimoclomol as an efficacious and well-tolerated disease-modifying treatment for NPC."

ShowHide Related Items >><<
ORPH Orphazyme
$5.33 /

+0.33 (+6.60%)

CYTR CytRx
/

+

CYTR CytRx
/

+

ORPH Orphazyme
$5.33 /

+0.33 (+6.60%)

06/21/21 Guggenheim
Orphazyme downgraded to Sell after CRL at Guggenheim
06/21/21 Guggenheim
Orphazyme downgraded to Sell from Neutral at Guggenheim
06/18/21 Cowen
Orphazyme downgraded to Market Perform from Outperform at Cowen
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
CYTR CytRx
/

+

  • 29
    Sep
ORPH Orphazyme
$5.33 /

+0.33 (+6.60%)

ORPH Orphazyme
$5.33 /

+0.33 (+6.60%)

Over a month ago
Earnings
CytRx highlights preliminary results of Cohort C of pancreatic cancer trial » 08:57
07/29/21
07/29
08:57
07/29/21
08:57
CYTR

CytRx

/

+

, IBRX

ImmunityBio

$11.45 /

+0.675 (+6.26%)

CytRx (CYTR) highlighted…

CytRx (CYTR) highlighted that ImmunityBio (IBRX) has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine . ImmunityBio's investigational treatment for cancer is designed to bolster a patient's own immune response to cancerous cells, augment that response with additional natural killer and T-cell therapies to overcome the cancer's resistance, and induce long-term T-cell memory to induce remission across multiple tumor types. As previously disclosed, CytRx out-licensed global development, manufacturing and commercialization rights for Aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343M in potential milestone payments and single and double-digit royalties on sales of Aldoxorubicin. To study the safety and early efficacy signals across multiple tumor types, ImmunityBio has launched a series of Quantitative Lifelong Trials QUILT. To date, the vaccine has been studied in more than 100 patients across multiple tumor types, including pancreatic, breast, colorectal, and head and neck cancers. Among these studies is QUILT 88, a Phase 2 trial that includes Aldoxorubicin and is studying the vaccine in metastatic pancreatic cancer patients. Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first quarter of 2022.

ShowHide Related Items >><<
IBRX ImmunityBio
$11.45 /

+0.675 (+6.26%)

CYTR CytRx
/

+

CYTR CytRx
/

+

IBRX ImmunityBio
$11.45 /

+0.675 (+6.26%)

06/04/21 Piper Sandler
ImmunityBio shared 'positive data points' on N-803 at ASCO, says Piper Sandler
04/07/21 Piper Sandler
ImmunityBio price target raised to $25 from $18 at Piper Sandler
Hot Stocks
CytRx in securities purchase pact for $10M with healthcare-focused investor » 08:16
07/13/21
07/13
08:16
07/13/21
08:16
CYTR

CytRx

/

+

CytRxy announced that it…

CytRxy announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10M. Under the terms of the Purchase Agreement, CytRx has agreed to sell 2,000,000 shares of its common stock at a purchase price of 88c per share for total gross proceeds of approximately $1.76M in a registered direct offering and 8,240 shares of Series C 10.00% Convertible Preferred Stock at a purchase price of $1,000 per share for total gross proceeds of approximately $8.24M in a concurrent private placement. The shares of the Preferred Stock will be convertible, upon shareholder approval as described below, into an aggregate of up to 9,363,637 shares of common stock at a conversion price of $88c per share. The Preferred Stock includes beneficial ownership limitations that preclude conversion that would result in the Investor owning in excess of 9.99% of the Company's outstanding shares of common stock. CytRx will also issue to the Investor an unregistered preferred investment option that allows for the purchase of up to 11,363,637 shares of common stock for additional gross proceeds of approximately $10M if the Investment Option is exercised in full. The exercise price for the Investment Option is 88c per share. The Investment Option shall have a term equal to five and one-half years commencing upon the Company increasing its authorized common stock following shareholder approval.

ShowHide Related Items >><<
CYTR CytRx
/

+

Over a quarter ago
Hot Stocks
CytRx notes Orphazyme regulatory update from FDA on arimoclomol » 16:44
06/18/21
06/18
16:44
06/18/21
16:44
CYTR

CytRx

$1.08 /

-1.74 (-61.70%)

, ORPH

Orphazyme

$7.31 /

-7.24 (-49.76%)

CytRx Corporation (CYTR)…

CytRx Corporation (CYTR) noted that Orphazyme A/S (ORPH) announced it has received a Complete Response Letter, or CRL, from the FDA following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C, or NPC. CytRx's drug candidate, arimoclomol, was sold to Orphazyme in exchange for milestone payments and royalties. Orphazyme's announcement disclosed that the FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale and, in particular, the swallow domain. Further, the FDA noted in the CRL that additional data are needed to bolster confirmatory evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA. A primary endpoint of the phase 2/3 clinical trial was progression in disease severity as measured by the 5-domain NPCCSS. This is a disease-specific measure of disease progression consisting of the five clinically most relevant domains to patients with NPC, caregivers and physicians. Orphazyme CEO Christophe Bourdon stated: "We are disheartened by the outcome of the FDA's review, given the urgent need for a new therapeutic option for NPC, but we remain committed to working with the regulators, with the goal of delivering arimoclomol to families managing this challenging disease. We will focus our efforts on pursuing the European regulatory approval, with CHMP opinion expected in Q4 2021 and potential Marketing Authorization in Q1 2022. We are assessing the potential path forward in the U.S. in partnership with the FDA. In the short-term, we will need to reduce our costs substantially and freeze all company efforts not related to clinical and regulatory activities to support approval for NPC." The outcome of the FDA decision has significant influence on Orphazyme's outlook for FY21. Orphazyme's cash position at year-end 2021 is now expected to be approximately $8, where it was previously $56M.

ShowHide Related Items >><<
ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

CYTR CytRx
$1.08 /

-1.74 (-61.70%)

CYTR CytRx
$1.08 /

-1.74 (-61.70%)

ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

06/18/21 Cowen
Orphazyme downgraded to Market Perform from Outperform at Cowen
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
  • 29
    Sep
ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

Conference/Events
LD Micro to hold a virtual conference » 04:55
06/10/21
06/10
04:55
06/10/21
04:55
LMB

Limbach Holding

$9.80 /

+0.39 (+4.14%)

, SPCB

SuperCom

$1.42 /

+0.11 (+8.40%)

, LODE

Comstock Mining

$4.17 /

-0.075 (-1.77%)

, AMST

Amesite

$2.20 /

-0.08 (-3.51%)

, EARS

Auris Medical

$3.56 /

-0.09 (-2.47%)

, URG

Ur-Energy

$1.59 /

-0.055 (-3.34%)

, NSPR

InspireMD

$6.11 /

+0.61 (+11.09%)

, ALLT

Allot Ltd.

$18.94 /

-0.28 (-1.46%)

, BCTX

BriaCell

$5.83 /

+0.695 (+13.53%)

, MFIN

Medallion Financial

$9.21 /

+0.185 (+2.05%)

, SCKT

Socket Mobile

$6.45 /

-0.475 (-6.86%)

, WATT

Energous

$3.36 /

+0.37 (+12.40%)

, OS

Oregon Steel Mills

/

+

, NMRD

Nemaura Medical

$15.05 /

+0.97 (+6.89%)

, LINK

Interlink Electronics

$11.20 /

+0.125 (+1.13%)

, GHSI

Guardion Health Sciences

$1.71 /

+0.01 (+0.59%)

, CYTR

CytRx

$2.00 /

+0.01 (+0.50%)

, PCSA

Processa Pharmaceuticals

$6.71 /

-0.23 (-3.31%)

, UUUU

Energy Fuels

$6.78 /

-0.2 (-2.87%)

, ACHV

Achieve Life Sciences

$8.54 /

-0.26 (-2.95%)

, KTRA

Kintara Therapeutics

$1.71 /

-0.015 (-0.87%)

, HJLI

Hancock Jaffe Laboratories

$6.42 /

-0.14 (-2.13%)

, VPRX

no symbol

/

+

, BLGO

BioLargo

/

+

LD Micro Invitational XI…

LD Micro Invitational XI Virtual Conference will be held on June 8-10.Webcast Link

ShowHide Related Items >><<
WATT Energous
$3.36 /

+0.37 (+12.40%)

VPRX no symbol
/

+

UUUU Energy Fuels
$6.78 /

-0.2 (-2.87%)

URG Ur-Energy
$1.59 /

-0.055 (-3.34%)

SPCB SuperCom
$1.42 /

+0.11 (+8.40%)

SCKT Socket Mobile
$6.45 /

-0.475 (-6.86%)

PCSA Processa Pharmaceuticals
$6.71 /

-0.23 (-3.31%)

NSPR InspireMD
$6.11 /

+0.61 (+11.09%)

NMRD Nemaura Medical
$15.05 /

+0.97 (+6.89%)

MFIN Medallion Financial
$9.21 /

+0.185 (+2.05%)

LODE Comstock Mining
$4.17 /

-0.075 (-1.77%)

LMB Limbach Holding
$9.80 /

+0.39 (+4.14%)

KTRA Kintara Therapeutics
$1.71 /

-0.015 (-0.87%)

HJLI Hancock Jaffe Laboratories
$6.42 /

-0.14 (-2.13%)

GHSI Guardion Health Sciences
$1.71 /

+0.01 (+0.59%)

EARS Auris Medical
$3.56 /

-0.09 (-2.47%)

CYTR CytRx
$2.00 /

+0.01 (+0.50%)

BCTX BriaCell
$5.83 /

+0.695 (+13.53%)

AMST Amesite
$2.20 /

-0.08 (-3.51%)

ALLT Allot Ltd.
$18.94 /

-0.28 (-1.46%)

LMB Limbach Holding
$9.80 /

+0.39 (+4.14%)

03/05/21
Fly Intel: Top five analyst initiations
03/05/21 Lake Street
Limbach Holding initiated with a Buy at Lake Street
SPCB SuperCom
$1.42 /

+0.11 (+8.40%)

LODE Comstock Mining
$4.17 /

-0.075 (-1.77%)

07/22/20 Noble Capital
Comstock Mining initiated with an Outperform at Noble Capital
AMST Amesite
$2.20 /

-0.08 (-3.51%)

12/28/20 Benchmark
Amesite initiated with a Speculative Buy at Benchmark
EARS Auris Medical
$3.56 /

-0.09 (-2.47%)

URG Ur-Energy
$1.59 /

-0.055 (-3.34%)

04/19/21 Alliance Global Partners
Ur-Energy initiated with a Buy at Alliance Global Partners
03/26/21 H.C. Wainwright
Ur-Energy price target raised to $2.10 from $1.40 at H.C. Wainwright
12/14/20 Cantor Fitzgerald
Cameco downgraded to Hold from Buy at Cantor Fitzgerald
NSPR InspireMD
$6.11 /

+0.61 (+11.09%)

10/16/20 Alliance Global Partners
InspireMD initiated with a Buy at Alliance Global Partners
ALLT Allot Ltd.
$18.94 /

-0.28 (-1.46%)

06/08/21 Lake Street
Allot Ltd. price target raised to $22 from $20 at Lake Street
BCTX BriaCell
$5.83 /

+0.695 (+13.53%)

MFIN Medallion Financial
$9.21 /

+0.185 (+2.05%)

05/06/21 B. Riley
Medallion Financial price target raised to $12 from $11 at B. Riley
04/07/21 B. Riley
Medallion Financial price target raised to $11 from $10 at B. Riley
02/19/21 B. Riley
Medallion Financial price target raised to $10 from $8 at B. Riley Securities
11/24/20 B. Riley
Medallion Financial resumed with a Buy at B. Riley Securities
SCKT Socket Mobile
$6.45 /

-0.475 (-6.86%)

WATT Energous
$3.36 /

+0.37 (+12.40%)

04/26/21 Roth Capital
Energous CEO leave to have limited impact, says Roth Capital
12/15/20 Roth Capital
Roth Capital backs Buy rating on Energous after securing FCC approval
12/02/20 Roth Capital
Roth keeps Buy rating on Energous as EU hearing aid customer identity revealed
08/19/20 Roth Capital
Energous partnership affirms expanding opportunity, says Roth Capital
OS Oregon Steel Mills
/

+

NMRD Nemaura Medical
$15.05 /

+0.97 (+6.89%)

LINK Interlink Electronics
$11.20 /

+0.125 (+1.13%)

GHSI Guardion Health Sciences
$1.71 /

+0.01 (+0.59%)

CYTR CytRx
$2.00 /

+0.01 (+0.50%)

PCSA Processa Pharmaceuticals
$6.71 /

-0.23 (-3.31%)

12/08/20 Benchmark
Processa Pharmaceuticals initiated with a Speculative Buy at Benchmark
10/28/20
Fly Intel: Top five analyst initiations
10/28/20 Craig-Hallum
Processa Pharmaceuticals initiated with a Buy at Craig-Hallum
UUUU Energy Fuels
$6.78 /

-0.2 (-2.87%)

05/26/21 Noble Capital
Energy Fuels upgraded to Outperform from Market Perform at Noble Capital
03/23/21 H.C. Wainwright
Energy Fuels price target raised to $7.25 from $4.50 at H.C. Wainwright
01/13/21 Cantor Fitzgerald
Energy Fuels upgraded to Buy from Hold at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Energy Fuels downgraded to Hold from Buy at Cantor Fitzgerald
ACHV Achieve Life Sciences
$8.54 /

-0.26 (-2.95%)

09/17/20 Lake Street
Achieve Life Sciences initiated with a Buy at Lake Street
KTRA Kintara Therapeutics
$1.71 /

-0.015 (-0.87%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
HJLI Hancock Jaffe Laboratories
$6.42 /

-0.14 (-2.13%)

09/03/20 Ladenburg
Hancock Jaffe Laboratories initiated with a Buy at Ladenburg
VPRX no symbol
/

+

BLGO BioLargo
/

+

WATT Energous
$3.36 /

+0.37 (+12.40%)

SPCB SuperCom
$1.42 /

+0.11 (+8.40%)

PCSA Processa Pharmaceuticals
$6.71 /

-0.23 (-3.31%)

MFIN Medallion Financial
$9.21 /

+0.185 (+2.05%)

LMB Limbach Holding
$9.80 /

+0.39 (+4.14%)

KTRA Kintara Therapeutics
$1.71 /

-0.015 (-0.87%)

GHSI Guardion Health Sciences
$1.71 /

+0.01 (+0.59%)

EARS Auris Medical
$3.56 /

-0.09 (-2.47%)

ALLT Allot Ltd.
$18.94 /

-0.28 (-1.46%)

  • 25
    May
  • 24
    Feb
  • 11
    Feb
  • 04
    Feb
  • 03
    Dec
  • 23
    Sep
LODE Comstock Mining
$4.17 /

-0.075 (-1.77%)

EARS Auris Medical
$3.56 /

-0.09 (-2.47%)

WATT Energous
$3.36 /

+0.37 (+12.40%)

SCKT Socket Mobile
$6.45 /

-0.475 (-6.86%)

LODE Comstock Mining
$4.17 /

-0.075 (-1.77%)

EARS Auris Medical
$3.56 /

-0.09 (-2.47%)

ALLT Allot Ltd.
$18.94 /

-0.28 (-1.46%)

ACHV Achieve Life Sciences
$8.54 /

-0.26 (-2.95%)

UUUU Energy Fuels
$6.78 /

-0.2 (-2.87%)

NMRD Nemaura Medical
$15.05 /

+0.97 (+6.89%)

LODE Comstock Mining
$4.17 /

-0.075 (-1.77%)

EARS Auris Medical
$3.56 /

-0.09 (-2.47%)

Conference/Events
LD Micro to hold a virtual conference » 11:46
06/09/21
06/09
11:46
06/09/21
11:46
LMB

Limbach Holding

$9.97 /

+0.56 (+5.95%)

, SPCB

SuperCom

$1.32 /

+0.01 (+0.76%)

, LODE

Comstock Mining

$4.42 /

+0.18 (+4.25%)

, AMST

Amesite

$2.30 /

+0.02 (+0.88%)

, EARS

Auris Medical

$3.66 /

+0.01 (+0.27%)

, URG

Ur-Energy

$1.60 /

-0.045 (-2.74%)

, NSPR

InspireMD

$6.17 /

+0.67 (+12.18%)

, ALLT

Allot Ltd.

$19.13 /

-0.09 (-0.47%)

, BCTX

BriaCell

$5.15 /

+0.015 (+0.29%)

, MFIN

Medallion Financial

$9.16 /

+0.135 (+1.50%)

, SCKT

Socket Mobile

$6.92 /

-0.005 (-0.07%)

, WATT

Energous

$3.43 /

+0.445 (+14.91%)

, OS

Oregon Steel Mills

/

+

, NMRD

Nemaura Medical

$14.75 /

+0.67 (+4.76%)

, LINK

Interlink Electronics

$11.08 /

+ (+0.00%)

, GHSI

Guardion Health Sciences

$1.75 /

+0.05 (+2.94%)

, CYTR

CytRx

$1.99 /

+0.41 (+25.95%)

, PCSA

Processa Pharmaceuticals

$6.89 /

-0.05 (-0.72%)

, UUUU

Energy Fuels

$7.01 /

+0.03 (+0.43%)

, ACHV

Achieve Life Sciences

$9.00 /

+0.2 (+2.27%)

, KTRA

Kintara Therapeutics

$1.74 /

+0.015 (+0.87%)

, HJLI

Hancock Jaffe Laboratories

$6.51 /

-0.05 (-0.76%)

, VPRX

no symbol

/

+

, BLGO

BioLargo

/

+

LD Micro Invitational XI…

LD Micro Invitational XI Virtual Conference will be held on June 8-10.Webcast Link

ShowHide Related Items >><<
WATT Energous
$3.43 /

+0.445 (+14.91%)

VPRX no symbol
/

+

UUUU Energy Fuels
$7.01 /

+0.03 (+0.43%)

URG Ur-Energy
$1.60 /

-0.045 (-2.74%)

SPCB SuperCom
$1.32 /

+0.01 (+0.76%)

SCKT Socket Mobile
$6.92 /

-0.005 (-0.07%)

PCSA Processa Pharmaceuticals
$6.89 /

-0.05 (-0.72%)

NSPR InspireMD
$6.17 /

+0.67 (+12.18%)

NMRD Nemaura Medical
$14.75 /

+0.67 (+4.76%)

MFIN Medallion Financial
$9.16 /

+0.135 (+1.50%)

LODE Comstock Mining
$4.42 /

+0.18 (+4.25%)

LMB Limbach Holding
$9.97 /

+0.56 (+5.95%)

KTRA Kintara Therapeutics
$1.74 /

+0.015 (+0.87%)

HJLI Hancock Jaffe Laboratories
$6.51 /

-0.05 (-0.76%)

GHSI Guardion Health Sciences
$1.75 /

+0.05 (+2.94%)

EARS Auris Medical
$3.66 /

+0.01 (+0.27%)

CYTR CytRx
$1.99 /

+0.41 (+25.95%)

BCTX BriaCell
$5.15 /

+0.015 (+0.29%)

AMST Amesite
$2.30 /

+0.02 (+0.88%)

ALLT Allot Ltd.
$19.13 /

-0.09 (-0.47%)

LMB Limbach Holding
$9.97 /

+0.56 (+5.95%)

03/05/21
Fly Intel: Top five analyst initiations
03/05/21 Lake Street
Limbach Holding initiated with a Buy at Lake Street
SPCB SuperCom
$1.32 /

+0.01 (+0.76%)

LODE Comstock Mining
$4.42 /

+0.18 (+4.25%)

07/22/20 Noble Capital
Comstock Mining initiated with an Outperform at Noble Capital
AMST Amesite
$2.30 /

+0.02 (+0.88%)

12/28/20 Benchmark
Amesite initiated with a Speculative Buy at Benchmark
EARS Auris Medical
$3.66 /

+0.01 (+0.27%)

URG Ur-Energy
$1.60 /

-0.045 (-2.74%)

04/19/21 Alliance Global Partners
Ur-Energy initiated with a Buy at Alliance Global Partners
03/26/21 H.C. Wainwright
Ur-Energy price target raised to $2.10 from $1.40 at H.C. Wainwright
12/14/20 Cantor Fitzgerald
Cameco downgraded to Hold from Buy at Cantor Fitzgerald
NSPR InspireMD
$6.17 /

+0.67 (+12.18%)

10/16/20 Alliance Global Partners
InspireMD initiated with a Buy at Alliance Global Partners
ALLT Allot Ltd.
$19.13 /

-0.09 (-0.47%)

06/08/21 Lake Street
Allot Ltd. price target raised to $22 from $20 at Lake Street
BCTX BriaCell
$5.15 /

+0.015 (+0.29%)

MFIN Medallion Financial
$9.16 /

+0.135 (+1.50%)

05/06/21 B. Riley
Medallion Financial price target raised to $12 from $11 at B. Riley
04/07/21 B. Riley
Medallion Financial price target raised to $11 from $10 at B. Riley
02/19/21 B. Riley
Medallion Financial price target raised to $10 from $8 at B. Riley Securities
11/24/20 B. Riley
Medallion Financial resumed with a Buy at B. Riley Securities
SCKT Socket Mobile
$6.92 /

-0.005 (-0.07%)

WATT Energous
$3.43 /

+0.445 (+14.91%)

04/26/21 Roth Capital
Energous CEO leave to have limited impact, says Roth Capital
12/15/20 Roth Capital
Roth Capital backs Buy rating on Energous after securing FCC approval
12/02/20 Roth Capital
Roth keeps Buy rating on Energous as EU hearing aid customer identity revealed
08/19/20 Roth Capital
Energous partnership affirms expanding opportunity, says Roth Capital
OS Oregon Steel Mills
/

+

NMRD Nemaura Medical
$14.75 /

+0.67 (+4.76%)

LINK Interlink Electronics
$11.08 /

+ (+0.00%)

GHSI Guardion Health Sciences
$1.75 /

+0.05 (+2.94%)

CYTR CytRx
$1.99 /

+0.41 (+25.95%)

PCSA Processa Pharmaceuticals
$6.89 /

-0.05 (-0.72%)

12/08/20 Benchmark
Processa Pharmaceuticals initiated with a Speculative Buy at Benchmark
10/28/20
Fly Intel: Top five analyst initiations
10/28/20 Craig-Hallum
Processa Pharmaceuticals initiated with a Buy at Craig-Hallum
UUUU Energy Fuels
$7.01 /

+0.03 (+0.43%)

05/26/21 Noble Capital
Energy Fuels upgraded to Outperform from Market Perform at Noble Capital
03/23/21 H.C. Wainwright
Energy Fuels price target raised to $7.25 from $4.50 at H.C. Wainwright
01/13/21 Cantor Fitzgerald
Energy Fuels upgraded to Buy from Hold at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Energy Fuels downgraded to Hold from Buy at Cantor Fitzgerald
ACHV Achieve Life Sciences
$9.00 /

+0.2 (+2.27%)

09/17/20 Lake Street
Achieve Life Sciences initiated with a Buy at Lake Street
KTRA Kintara Therapeutics
$1.74 /

+0.015 (+0.87%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
HJLI Hancock Jaffe Laboratories
$6.51 /

-0.05 (-0.76%)

09/03/20 Ladenburg
Hancock Jaffe Laboratories initiated with a Buy at Ladenburg
VPRX no symbol
/

+

BLGO BioLargo
/

+

WATT Energous
$3.43 /

+0.445 (+14.91%)

SPCB SuperCom
$1.32 /

+0.01 (+0.76%)

PCSA Processa Pharmaceuticals
$6.89 /

-0.05 (-0.72%)

MFIN Medallion Financial
$9.16 /

+0.135 (+1.50%)

LMB Limbach Holding
$9.97 /

+0.56 (+5.95%)

KTRA Kintara Therapeutics
$1.74 /

+0.015 (+0.87%)

GHSI Guardion Health Sciences
$1.75 /

+0.05 (+2.94%)

EARS Auris Medical
$3.66 /

+0.01 (+0.27%)

ALLT Allot Ltd.
$19.13 /

-0.09 (-0.47%)

  • 25
    May
  • 24
    Feb
  • 11
    Feb
  • 04
    Feb
  • 03
    Dec
  • 23
    Sep
LODE Comstock Mining
$4.42 /

+0.18 (+4.25%)

EARS Auris Medical
$3.66 /

+0.01 (+0.27%)

WATT Energous
$3.43 /

+0.445 (+14.91%)

SCKT Socket Mobile
$6.92 /

-0.005 (-0.07%)

LODE Comstock Mining
$4.42 /

+0.18 (+4.25%)

EARS Auris Medical
$3.66 /

+0.01 (+0.27%)

ALLT Allot Ltd.
$19.13 /

-0.09 (-0.47%)

ACHV Achieve Life Sciences
$9.00 /

+0.2 (+2.27%)

UUUU Energy Fuels
$7.01 /

+0.03 (+0.43%)

NMRD Nemaura Medical
$14.75 /

+0.67 (+4.76%)

LODE Comstock Mining
$4.42 /

+0.18 (+4.25%)

EARS Auris Medical
$3.66 /

+0.01 (+0.27%)

Syndicate
CytRx files to sell 2M shares of common stock  06:38
04/22/21
04/22
06:38
04/22/21
06:38
CYTR

CytRx

$2.12 /

+0.12 (+6.00%)

 
ShowHide Related Items >><<
CYTR CytRx
$2.12 /

+0.12 (+6.00%)

Hot Stocks
CytRx highlights NantKwest, ImmunityBio clinical trials of immunotherapy » 08:13
01/15/21
01/15
08:13
01/15/21
08:13
CYTR

CytRx

$0.30 /

+ (+0.00%)

, NK

NantKwest

$17.82 /

+3.04 (+20.57%)

CytRx (CYTR) highlighted…

CytRx (CYTR) highlighted that NantKwest (NK) and ImmunityBio have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy - which include CytRx's licensed drug aldoxorubicin - for locally advanced or metastatic pancreatic cancer have produced early indications of increased survival rates for patients with no other approved treatment options. Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer.

ShowHide Related Items >><<
NK NantKwest
$17.82 /

+3.04 (+20.57%)

CYTR CytRx
$0.30 /

+ (+0.00%)

CYTR CytRx
$0.30 /

+ (+0.00%)

NK NantKwest
$17.82 /

+3.04 (+20.57%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$17.82 /

+3.04 (+20.57%)

NK NantKwest
$17.82 /

+3.04 (+20.57%)

Hot Stocks
CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 » 14:07
12/31/20
12/31
14:07
12/31/20
14:07
CYTR

CytRx

$0.30 /

+ (+0.00%)

, ORPH

Orphazyme

$10.90 /

+ (+0.00%)

CytRx (CYTR) provided an…

CytRx (CYTR) provided an update on the U.S. Food and Drug Administration's review of Orphazyme A/S's (ORPH) New Drug Application for arimoclomol to treat Niemann-Pick Disease Type C. According to Orphazyme, the FDA has extended the review period with a standard extension of three months in order to complete the NDA review. The updated Prescription Drug User Fee Act, "PDUFA," target action date is June 17, 2021. Orphazyme disclosed that the FDA has confirmed that the NDA remains under Priority Review. The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety or effectiveness, diagnosis, or prevention of serious conditions. Notably, the FDA has confirmed that the extension does not impede eligibility for a Pediatric Rare Disease Priority Review Voucher. Arimoclomol previously received the FDA's Fast-Track and Breakthrough Therapy Designations for NPC as well as Orphan Drug and Rare Pediatric Disease Designations. If approved in the U.S., arimoclomol will be the first and only approved medicine for NPC. In November 2020, Orphazyme also submitted a Marketing Authorisation Application to the European Medicines Agency for arimoclomol to treat NPC.

ShowHide Related Items >><<
ORPH Orphazyme
$10.90 /

+ (+0.00%)

CYTR CytRx
$0.30 /

+ (+0.00%)

CYTR CytRx
$0.30 /

+ (+0.00%)

ORPH Orphazyme
$10.90 /

+ (+0.00%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
  • 29
    Sep
ORPH Orphazyme
$10.90 /

+ (+0.00%)

Hot Stocks
CytRx comments on proposed combination of ImmunityBio and NantKwest » 08:10
12/22/20
12/22
08:10
12/22/20
08:10
CYTR

CytRx

$0.30 /

+ (+0.00%)

, NK

NantKwest

$16.02 /

+5.78 (+56.45%)

CytRx (CYTR)…

CytRx (CYTR) congratulated ImmunityBio and NantKwest on their proposed merger and announced plans to create a leading immunotherapy and cell therapy company. CytRx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343M in potential milestone payments and single and double-digit royalties on sales of aldoxorubicin. In their announcement, ImmunityBio and NantKwest highlighted that the combined entity will have a broad clinical-stage pipeline - including 13 assets in clinical trials and 11 in Phase 2 to 3 programs - as well as a robust early-stage pipeline to address other difficult to treat cancers. The companies also noted that the combination of NantKwest's Natural Killer cell platform and ImmunityBio's immunotherapy platforms - including albumin-based tumor microenvironment immune modulators- have already resulted in complete responses in aggressive and late-stage metastatic cancers. To date, complete responses have been noted in patients with second-line or greater metastatic pancreatic cancer, triple-negative breast cancer, head and neck cancer, and Merkel Cell Carcinoma. Notably, ImmunityBio and NantKwest recently announced the addition of a third cohort to an ongoing Phase 2 study of a novel combination immunotherapy - which includes aldoxorubicin - for locally advanced or metastatic pancreatic cancer (QUILT-88). As previously outlined in CytRx's October 7, 2020 announcement regarding the successful treatment delivered to former Nevada Senator Harry Reid for his stage IV pancreatic cancer, the randomized, open-label study is evaluating the safety and efficacy of a combination immunotherapy that includes aldoxorubicin, ImmunityBio's IL-15 superagonist Anktiva NantKwest's PD-L1 t-haNK and standard of care. The study results will be compared to standard of care chemotherapy for first- and second-line treatment. However, the third-line cohort is a single arm with no comparator and each cohort will be evaluated independently to provide a more precise comparative.

ShowHide Related Items >><<
NK NantKwest
$16.02 /

+5.78 (+56.45%)

CYTR CytRx
$0.30 /

+ (+0.00%)

CYTR CytRx
$0.30 /

+ (+0.00%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$16.02 /

+5.78 (+56.45%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.